Evidence map›Paper›PMID 41398103›Full record

ReviewHandbook of experimental pharmacology2026

Comparison of the Biologic Activity of Different Species of Heparin.

Walter Jeske

Abstract readReviewComparative Study
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Walter JeskeLoyola University Chicago, Cardiovascular Research Institute, Maywood, IL, USA. wjeske@luc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heparin and related low molecular weight heparin derivatives remain critical drugs for the prevention and treatment of thrombotic conditions. Concerns relating to the stability and sufficiency of the porcine intestinal mucosa supplies from which most heparin is currently derived have spurred an interest in identifying other sources for heparin. Commercial quantities of heparin may be obtained from cow and sheep intestine, and heparin or heparin-like material has been identified in a number of other species. Being biologic in nature, these heparins exhibit unique structural and functional profiles. This chapter summarizes our current understanding of these heparins.

Indexed as

AnticoagulantsHeparinAnimalsCattleHeparin, Low-Molecular-WeightHumansSheepSpecies SpecificitySwineAnticoagulantsHeparinHeparin, Low-Molecular-WeightAnticoagulantAntithromboticBiologicBleedingHeparin

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.